Project NextGen: Developing the Next Generation of COVID-19 Vaccines and Therapeutics to Respond to the Present and Prepare for the Future
KA Hofmeyer, CL Ventura, KL Armstrong… - Clinical Infectious …, 2024 - academic.oup.com
Abstract Coronavirus disease 2019 (COVID-19) epidemiology and product landscapes have
changed considerably since onset of the pandemic. Safe and effective vaccines and …
changed considerably since onset of the pandemic. Safe and effective vaccines and …
How Immunocompromised Hosts Were Left Behind in the Quest to Control the Covid-19 Pandemic
The immunocompromised population was disproportionately affected by the SARS-CoV-2
pandemic. However, these individuals were largely excluded from clinical trials of vaccines …
pandemic. However, these individuals were largely excluded from clinical trials of vaccines …
Anti-SARS-CoV-2 glyco-humanized polyclonal antibody XAV-19: phase II/III randomized placebo-controlled trial shows acceleration to recovery for mild to moderate …
G Poulakou, PJ Royer, N Evgeniev, G Evanno… - Frontiers in …, 2024 - frontiersin.org
Introduction XAV-19 is a glyco-humanized swine polyclonal antibody targeting SARS-CoV-2
with high neutralizing activity. The safety and clinical efficacy of XAV-19 were investigated in …
with high neutralizing activity. The safety and clinical efficacy of XAV-19 were investigated in …
[HTML][HTML] Humoral immunity to SARS-CoV-2 in kidney transplant recipients and dialysis patients: IgA and IgG patterns unraveled after SARS-CoV-2 infection and …
C De Bouver, J Bouziotis, VPWM Wijtvliet, KK Ariën… - Virology Journal, 2024 - Springer
Abstract Background Infection with SARS-CoV-2 in high-risk groups such as kidney
transplant and dialysis patients is shown to be associated with a more serious course of the …
transplant and dialysis patients is shown to be associated with a more serious course of the …
Vaccination strategies for patients under monoclonal antibody and other biological treatments: an updated comprehensive review based on EMA authorizations to …
M Rivera-Izquierdo, A Morales-Portillo… - Expert Review of …, 2024 - Taylor & Francis
Introduction Monoclonal antibodies (mAbs) and other biological agents are being
increasingly approved in the last years with very different indications. Their highly …
increasingly approved in the last years with very different indications. Their highly …
Predictive profiling of SARS-CoV-2 variants by deep mutational learning
The continual evolution of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-
2) and the emergence of variants that show resistance to vaccines and neutralizing …
2) and the emergence of variants that show resistance to vaccines and neutralizing …
[HTML][HTML] An update on Long COVID
G Grohmann, R Booy - Microbiology Australia, 2024 - CSIRO Publishing
'Long COVID'is a major dilemma, difficult to diagnose and even more challenging to treat.
Millions are still being affected globally and~ 10% of people experience Long COVID …
Millions are still being affected globally and~ 10% of people experience Long COVID …
[HTML][HTML] Harnessing immunity: Immunomodulatory therapies in COVID-19
T Velikova, H Valkov, A Aleksandrova… - World Journal of …, 2024 - ncbi.nlm.nih.gov
An overly exuberant immune response, characterized by a cytokine storm and uncontrolled
inflammation, has been identified as a significant driver of severe coronavirus disease 2019 …
inflammation, has been identified as a significant driver of severe coronavirus disease 2019 …
Increased Risk of Invasive Aspergillosis in Immunocompromised Patients With Persistent SARS-CoV-2 Viral Shedding> 8 Weeks, Retrospective Case-control Study
C Melenotte, N Chavarot, AS L'Honneur… - Open Forum …, 2024 - academic.oup.com
Background Immunocompromised patients now represent the population most at risk for
severe coronavirus disease 2019. Persistent severe acute respiratory syndrome coronavirus …
severe coronavirus disease 2019. Persistent severe acute respiratory syndrome coronavirus …